.. ASI launches GenASIs advanced cytogenetic and pathology platforms Applied Spectral Imaging (ASI, announced today general availability of the GenASIs automated imaging platforms for genetic and pathology evaluation. The GenASIs advanced cytogenetic and pathology platforms are the base of ASI’s fresh offering. With its excellent imaging and analysis features, ASI provides condition of the creative art diagnostic aids, offering pathologists and cytogeneticists accurate genetic and pathology evaluation.Peter Campochiaro, M.D., will present results at Angiogenesis, Degeneration and Exudation 2011, 12 February, in Miami, Fla. Alimera Sciences, Inc. Individuals in the trials were randomized to receive either high dosage ILUVIEN, low dose control or ILUVIEN treatment. Alimera previously presented data for both the high and low dosage patient results in month 24. Predicated on these data, Alimera submitted a fresh Drug Program on June 29, 2010 for approval of only the low dose. Therefore, only the reduced dose data is discussed and presented in this release.